Skip to main content

Advertisement

Table 9 Longitudinal studies on serum CA125 levels and survival in ovarian cancer

From: Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature

First Author, Year, Study Place Data Collection Study Design Sample Size Groups being Compared RR/HR, (95% CI), P-Value Conclusion Variables Adjusted for
Riedinger JM, 2007, France [47] 1988 to 1996 Multicentric study 494 ≥ 75% decrease, < 75% decrease or increase Univariate- 1.92 (1.34--2.74), < 0.0001 3.08 (2.10--4.50), < 0.0001
Multivariate-0.90 (0.59--1.39), NS
0.97 (0.59--1.59), NS
The CA125 change after first course of CT was independent prognostic factors for both achievement of pathological complete response and overall survival. Age, Histology
FIGO stage, Residual tumor
Markman M, 2006, USA [37] NA Longitudinal study 291 I > 100, ≤ 35 u/ml
II 36--99, ≤ 35 u/ml
III > 100, 36--99 u/ml
I - 3.0 (1.7--8.6), 0.0001
II - 1.6 (0.9--2.8), 0.09
III-1.8 (1.0--3.5), 0.07
While pretreatment CA125 values did not correlate with survival, the concentration of CA125 8 weeks after initiation of therapy was a powerful independent prognostic factor. Age, performance status, disease stage, measurable disease, treatment, tumor necrosis, stromal sclerosis